Treatment for Narcolepsy

Initial Management Approach

The American Academy of Sleep Medicine recommends optimizing any underlying medical, neurologic, or psychiatric disorders and carefully withdrawing sedating medications if possible, before initiating pharmacotherapy, to ensure adequate nighttime sleep opportunity and exclude sleep deprivation as a cause of excessive sleepiness 5

The American Academy of Sleep Medicine strongly recommends modafinil, pitolisant, sodium oxybate, and solriamfetol as first-line treatments for narcolepsy in adults, with modafinil being the most established option for excessive daytime sleepiness and sodium oxybate being the only medication that effectively treats both excessive daytime sleepiness and cataplexy 1, 2, 3, 4
Modafinil provides clinically significant improvements in excessive daytime sleepiness, disease severity, and quality of life based on moderate-quality evidence from 9 RCTs and 4 observational studies, with a dosing of 200-400 mg daily, taken in the morning 1, 4
Solriamfetol has the strongest evidence base for excessive daytime sleepiness with high-quality evidence from 3 RCTs, and is a FDA Schedule IV controlled substance 2, 3
Sodium oxybate is the only medication that effectively treats both excessive daytime sleepiness and cataplexy, with moderate-quality evidence from 6 RCTs and 6 observational studies, and is a FDA Schedule III controlled substance 1, 3, 4

Behavioral modifications such as maintaining a regular sleep-wake schedule, scheduling two short naps, avoiding heavy meals and alcohol use, and implementing good sleep hygiene techniques are beneficial to most patients 5, 4

The Epworth Sleepiness Scale can be used to quantify sleepiness and monitor treatment response, and a thorough physical examination including neurologic evaluation should be conducted regularly 5, 4

In pediatric patients, modafinil and sodium oxybate are conditionally recommended, with a starting dose of 100 mg once upon awakening for modafinil, and close monitoring for Stevens-Johnson syndrome 4
In pregnant and breastfeeding women, all narcolepsy medications may cause fetal harm, and a risk-benefit assessment must prioritize maternal safety and functional capacity 1, 2, 3

Inadequate dosing or premature discontinuation of medication can lead to inadequate management of narcolepsy, and medication selection errors can occur if solriamfetol, armodafinil, modafinil, dextroamphetamine, and methylphenidate are used to treat cataplexy 3, 4